AI assistant
ABBOTT LABORATORIES — Director's Dealing 2021
Feb 24, 2021
29777_dirs_2021-02-23_108476b2-c96f-444b-9741-ba27f782a6bb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2021-02-19
Reporting Person: BIRD ROGER (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-19 | Common shares without par value | A | 13004 | — | Acquired | 69634 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-19 | Option (right to buy) | $124.04 | A | 66658 | Acquired | 2031-02-18 | Common Shares (66658) | Direct |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,219 on February 19, 2022, 22,219 on February 19, 2023, and 22,220 on February 19, 2024.